GlassScriptPhysician profile
Peter C Schalock
NPI 1265490866
$441.06
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.63 · 2020: $127 · 2021: $194 · 2022: $96.37.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $158.07 | 2021-2022 | |
| Janssen Biotech, INC. | $99.99 | 2020 | |
| Abbvie INC. | $72.94 | 2019-2021 | |
| Leo Pharma INC. | $37.10 | 2020-2021 | |
| Lilly USA, LLC | $24.93 | 2021 | |
| Genzyme Corporation | $24.66 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $23.37 | 2020-2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Schalock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.